Zacks Research Comments on AngioDynamics, Inc.’s Q2 2025 Earnings (NASDAQ:ANGO)

AngioDynamics, Inc. (NASDAQ:ANGOFree Report) – Equities research analysts at Zacks Research cut their Q2 2025 earnings per share (EPS) estimates for AngioDynamics in a report released on Monday, May 27th. Zacks Research analyst D. Dey now forecasts that the medical instruments supplier will post earnings of ($0.15) per share for the quarter, down from their prior forecast of ($0.14). The consensus estimate for AngioDynamics’ current full-year earnings is ($0.57) per share. Zacks Research also issued estimates for AngioDynamics’ Q3 2025 earnings at ($0.16) EPS, Q4 2025 earnings at ($0.09) EPS, FY2025 earnings at ($0.61) EPS, Q1 2026 earnings at ($0.18) EPS, Q2 2026 earnings at ($0.08) EPS, Q3 2026 earnings at ($0.02) EPS and FY2026 earnings at ($0.29) EPS.

AngioDynamics (NASDAQ:ANGOGet Free Report) last released its quarterly earnings data on Thursday, April 4th. The medical instruments supplier reported ($0.16) EPS for the quarter, missing the consensus estimate of ($0.14) by ($0.02). AngioDynamics had a negative net margin of 60.21% and a negative return on equity of 3.48%.

Several other analysts have also recently weighed in on the stock. HC Wainwright reiterated a “buy” rating and issued a $14.00 price objective on shares of AngioDynamics in a research note on Wednesday, May 22nd. Oppenheimer upgraded AngioDynamics from a “market perform” rating to an “outperform” rating and set a $12.00 target price on the stock in a research report on Friday, April 5th. One investment analyst has rated the stock with a hold rating and four have given a buy rating to the stock. Based on data from, AngioDynamics has a consensus rating of “Moderate Buy” and a consensus price target of $13.25.

Get Our Latest Report on ANGO

AngioDynamics Trading Up 2.3 %

NASDAQ:ANGO opened at $6.27 on Thursday. The stock has a 50 day simple moving average of $6.12 and a 200 day simple moving average of $6.33. The stock has a market cap of $251.18 million, a P/E ratio of -1.30 and a beta of 0.67. AngioDynamics has a 1-year low of $5.26 and a 1-year high of $11.38.

Insider Activity at AngioDynamics

In related news, CEO James C. Clemmer acquired 10,000 shares of the firm’s stock in a transaction that occurred on Monday, April 8th. The stock was acquired at an average cost of $6.70 per share, for a total transaction of $67,000.00. Following the completion of the acquisition, the chief executive officer now directly owns 539,066 shares of the company’s stock, valued at approximately $3,611,742.20. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. 5.10% of the stock is owned by company insiders.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of ANGO. Armistice Capital LLC acquired a new position in shares of AngioDynamics during the 4th quarter valued at $6,272,000. Fund 1 Investments LLC purchased a new stake in shares of AngioDynamics in the fourth quarter valued at about $3,896,000. Western Standard LLC increased its stake in AngioDynamics by 878.5% in the 1st quarter. Western Standard LLC now owns 523,393 shares of the medical instruments supplier’s stock valued at $3,072,000 after buying an additional 469,906 shares during the last quarter. Acadian Asset Management LLC bought a new stake in AngioDynamics during the third quarter worth $2,630,000. Finally, Jacobs Levy Equity Management Inc. raised its stake in shares of AngioDynamics by 62.4% during the 3rd quarter. Jacobs Levy Equity Management Inc. now owns 713,899 shares of the medical instruments supplier’s stock worth $5,219,000 after purchasing an additional 274,210 shares during the period. Institutional investors and hedge funds own 89.43% of the company’s stock.

AngioDynamics Company Profile

(Get Free Report)

AngioDynamics, Inc provides invasive medical devices used by professional healthcare providers for vascular access, surgery, peripheral vascular disease and oncology in the United States and internationally. It offers Auryon Atherectomy system that is designed to deliver an optimized wavelength, pulse width, and amplitude to remove lesions while preserving vessel wall endothelium for treatment of peripheral arterial disease.

Read More

Earnings History and Estimates for AngioDynamics (NASDAQ:ANGO)

Receive News & Ratings for AngioDynamics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AngioDynamics and related companies with's FREE daily email newsletter.